Harmony Biosciences (NASDAQ:HRMY – Get Free Report) is one of 894 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare Harmony Biosciences to related businesses based on the strength of its risk, dividends, earnings, profitability, analyst recommendations, valuation and institutional ownership.
Valuation & Earnings
This table compares Harmony Biosciences and its competitors top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Harmony Biosciences | $989.36 million | $158.69 million | 11.00 |
| Harmony Biosciences Competitors | $18.73 billion | $3.24 billion | 559.21 |
Harmony Biosciences’ competitors have higher revenue and earnings than Harmony Biosciences. Harmony Biosciences is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Insider & Institutional Ownership
86.2% of Harmony Biosciences shares are held by institutional investors. Comparatively, 32.7% of shares of all “Pharmaceuticals” companies are held by institutional investors. 11.0% of Harmony Biosciences shares are held by insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Profitability
This table compares Harmony Biosciences and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Harmony Biosciences | 18.05% | 18.55% | 13.24% |
| Harmony Biosciences Competitors | -2,398.26% | -203.62% | -15.08% |
Volatility & Risk
Harmony Biosciences has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500.Comparatively, Harmony Biosciences’ competitors have a beta of -0.04, suggesting that their average share price is 104% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current ratings for Harmony Biosciences and its competitors, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Harmony Biosciences | 1 | 5 | 6 | 1 | 2.54 |
| Harmony Biosciences Competitors | 7845 | 13798 | 25818 | 1039 | 2.41 |
Harmony Biosciences presently has a consensus target price of $48.00, suggesting a potential upside of 44.47%. As a group, “Pharmaceuticals” companies have a potential upside of 24.20%. Given Harmony Biosciences’ stronger consensus rating and higher possible upside, analysts clearly believe Harmony Biosciences is more favorable than its competitors.
Summary
Harmony Biosciences beats its competitors on 8 of the 13 factors compared.
Harmony Biosciences Company Profile
Harmony Biosciences is a biopharmaceutical company focused on developing and commercializing treatments for people living with rare neurological diseases. The company’s work centers on therapies intended to address significant unmet medical needs. Its lead product, WAKIX (pitolisant), is approved in the United States to treat excessive daytime sleepiness or cataplexy in adults and pediatric patients aged 6 years and older with narcolepsy. Harmony launched WAKIX in the United States in 2019. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony primarily serves the U.S. market.
Receive News & Ratings for Harmony Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harmony Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
